XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Colon Channel
subscribe to Colon newsletter

Latest Research : Cancer : Colon

   DISCUSS   |   EMAIL   |   PRINT
$2.6 million in grants for metastatic colon cancer research
Jul 8, 2006, 21:59, Reviewed by: Dr. Priya Saxena

We offer our sincere congratulations to the investigators, and anticipate they will make substantial contributions to this field of cancer research."


 
The American Association for Cancer Research announces the first 11 recipients of the new Jeannik M. Littlefield-AACR Grants in Metastatic Colon Cancer Research. The awards, ranging to $250,000, were established in February 2006, to support innovative research projects designed to accelerate the discovery and development of new agents to treat metastatic colon cancer. Grant awards were selected through a rigorous and highly competitive process by a committee of accomplished senior scientists. AACR is currently distributing a total of $2,644,977 to the successful investigators.

"Among the 114 applications submitted, these 11 awardees were judged to have the most merit," said David Irwin, Ph.D., managing director of the Science and Education Division of the AACR. "We offer our sincere congratulations to the investigators, and anticipate they will make substantial contributions to this field of cancer research."

The Jeannik M. Littlefield-AACR Grants in Metastatic Colon Cancer Research are sponsored by Jacques and Sandy Littlefield of Portolo Valley, California, who donated $3 million to the AACR in late 2005. They are named for Mr. Littlefield's mother.

Recipients of the 2006 Jeannik M. Littlefield-AACR Grants in Metastatic Colon Cancer Research are:

Peter Carmeliet, M.D., Ph.D., Flanders Interuniversity Institute for Biotechnology, "Preclinical Development of anti-P1GF Antibodies for Metastatic Colon Cancer." In the quest to block angiogenesis, this study will test a homologue of VEGF P1GF. Antibodies to P1GF will be used in cell lines and xenograft models. The approach has strong potential for clinical application because blocking P1GF should not interfere with normal angiogenesis.

Steven A. Curley, M.D., University of Texas M.D. Anderson Cancer Center, "Carbon Nanotubules and Gold Nanoparticles as Radiofrequency Targets." The goals are to couple antibodies to nanotubules and gold particles to affect specific homing to metastases. Inoperable metastases can then be thermally ablated using microwaves.

Wafik El-Deiry, M.D., Ph.D., University of Pennsylvania, "Novel Therapy for Resistant Metastatic Colon Cancer." The goals are to define the mechanisms in colon cancer that make tumor cells resistant to apoptosis, and develop combination drug therapies that can reverse the apoptotic defect.

Edgar G. Engelman, M.D., Stanford University, "T-Cell Signaling in Metastatic Colon Cancer." This study will examine the failure of the immune system to detect colon cancer cells with the goal of identifying and profiling tumor-associated signaling abnormalities in T-cells. This will affect choice of therapy and will show whether signalling abnormalities can be reversed using immunotherapy.

Douglas V. Faller, M.D., Ph.D., Boston University School of Medicine, "PKC-Delta as a Therapeutic Target in Colon Cancer." The approach is to inhibit PKC-delta which is not critical for normal cellular growth but which, in tumor cells, inhibits Ras-mediated apoptosis. Molecular strategies will identify more active and more specific inducers of the Ras-mediated apoptotic pathway.

Robert D. Ladner, Ph.D., University of Southern California, "Histone Deacetylase Inhibitors for the Treatment of Metastatic Colon Cancer." New approaches will be developed to enhance the effectiveness of 5FU using histone de-acetylase inhibitors.

Eric Lagasse, Ph.D., PharmD, University of Pittsburgh, "Metastatic Colon Cancer, Stem Cells and Bioreactors." Using an artificial bioreactor that models the environment in liver and colon cancer, stem cells will be identified and expanded in vitro. Therapy will then be refined and customized preclinically before being administered to patients.

Nouri Neamati, Ph.D., University of Southern California, "Preclinical Development of SC144 in Metastatic Colon Cancer." A new agent, SC144 has been shown to cause up-regulation of IL24 - a very potent anticancer protein. SC144 will be fully evaluated in mouse models and then, potentially, trials will be extended to humans.

Boris C. Pasche, M.D., Ph.D., Northwestern University, "Targeting the TGFBR1*6A in Metastatic Colon Cancer." This study will use antibodies to TGFB and assess their effects on colon tumor growth in mice. A humanized antibody will be used in a Phase I/II clinical trial.

Gary K. Schwartz, M.D., Memorial Sloan Kettering Cancer Center, "Targeting the Notch Signaling Pathway in Metastatic Colon Cancer." The effectiveness of combining notch and ras inhibitors such as gamma secretase inhibitors will be examined in colon cancer cells as a prerequisite to designing a Phase I clinical trial.

Oliver Stoeltzing, M.D., Universitaet Regensburg, "The Role of Hsp 90 in Hepatic Growth of Colorectal Cancer Metastases." Using colon cell lines and xenografts, this study will examine the role of tissue hypoxia in colorectal hepatic metastases and the suitability of targeting Hsp 90 for molecular targeted therapies.

 

-
 

http://www.aacr.org/

 
Subscribe to Colon Newsletter
E-mail Address:

 

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 24,000 basic, translational, and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 60 other countries. AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment, and patient care. AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent publication, CR, is a magazine for cancer survivors, patient advocates, their families, physicians, and scientists. It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.



Related Colon News

Regular aerobics protects men from colon cancer
Role for MicroRNAs in Oxygenation, Nourishing of Colon Tumors
New genetic test to spotlight heightened bowel cancer risk
$2.6 million in grants for metastatic colon cancer research
NSAIDs don't reduce colorectal cancer risk in chronic smokers
Timing of radiation treatments for colon cancer may need adjusting
How growth hormone therapy can lead to colon polyps
Review study sets treatment standard for elderly with colon cancer
Eating red meat could damage DNA by N-nitrosocompounds
Diet pattern may effect the development of colon cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us